In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

Rudalska, Ramona, Dauch, Daniel, Longerich, Thomas, McJunkin, Katherine, Wuestefeld, Torsten, Kang, Tae-Won, Hohmeyer, Anja, Pesic, Marina +13 more·2014·Nature Medicine

DOI 10.1038/nm.3679

Cited by (284)

Items 101–200 of 284

Mitochondrial Processing Peptidases—Structure, Function and the Role in Human Diseases
Nina Kunová, Henrieta Havalová, Gabriela Ondrovičová, Barbora Stojkovičová, Jacob Bauer, Vladena Bauerová‐Hlinková, Vladimír Pevala, Eva Kutějová · 2022 · International Journal of Molecular Sciences
Tutorial: design and execution of CRISPR in vivo screens
Christian Joerg Braun, Andrés Carbonell Adames, Dieter Saur, Roland Rad · 2022 · Nature Protocols
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
John Michael Krill-Burger, Joshua M. Dempster, Ashir A. Borah, Brenton R. Paolella, David E. Root, Todd R. Golub, Jesse S. Boehm, William C. Hahn, James M. McFarland, Francisca Vázquez et al. · 2023 · Genome biology
Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma
Jing Ping Tang, Chengjun Sui, Dongfang Wang, Xinyuan Lu, Guijuan Luo, Qing Zhao, Qiuyu Lian, Seogsong Jeong, Ximeng Lin, Yanjing Zhu et al. · 2020 · Theranostics
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
María Luz Morales, Alicia Arenas, Alejandra Ortiz-Ruiz, Alejandra Leivas, Inmaculada Rapado, Alba Rodríguez-García, Nerea Castro, Ivana Zagorac, Miguel Quintela-Fandiño, Gonzalo Goméz-López et al. · 2019 · Scientific Reports
CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice
Mingming Gao, Dexi Liu · 2017 · Cancer Biology & Therapy
Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti‐cancer therapy
Hye‐Lim Ju, Kwang‐Hyub Han, Jong Doo Lee, Simon Weonsang Ro · 2015 · International Journal of Cancer
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl- d -aspartate (NMDA) Receptor Antagonist
Mikko Gynther, Ilaria Proietti Silvestri, Jacob C. Hansen, Kasper Bø Hansen, Tarja Malm, Yevheniia Ishchenko, Younes Larsen, Liwei Han, Silke Kayser, Seppo O. K. Auriola et al. · 2017 · Journal of Medicinal Chemistry
Implications of genetic heterogeneity in hepatocellular cancer
Akanksha Suresh, Renumathy Dhanasekaran · 2022 · Advances in cancer research
Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus
Dvora Witt-Kehati, Alexandra Fridkin, Maya Bitton Alaluf, Romy R. Zemel, Amir Shlomai · 2018 · Translational Oncology
Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR
Weiqing Shao, Wenwei Zhu, Jing Lin, Mengjun Luo, Zhifei Lin, Lu Lu, Huliang Jia, Lun–Xiu Qin, Ming Lü, Jinhong Chen · 2019 · Neoplasia
Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications
Mario Romeo, Marcello Dallio, Flavia Scognamiglio, Lorenzo Ventriglia, Marina Cipullo, Annachiara Coppola, Chiara Tammaro, Giuseppe Scafuro, Patrizia Iodice, Alessandro Federico · 2023 · Cancers
Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease
Chung-Lin Hung, Chia-Shen Yen, Hung-Wen Tsai, Yu‐Chieh Su, Chia-Jui Yen · 2015 · BMC Cancer
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma
Antonio Facciorusso, Raffaele Licinio, Brian Irving Carr, Alfredo Di Leo, M. Barone · 2015 · Expert Review of Gastroenterology & Hepatology
Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment
Ali Attiq, Sheryar Afzal · 2023 · Frontiers in Pharmacology
Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion
Leticia Serrano‐Oviedo, Marta Ortega‐Muelas, Jesús García‐Cano, María Llanos Valero, Francisco J. Cimas, Raquel Pascual‐Serra, Diego M. Fernández‐Aroca, Olga Roche, María José Ruiz‐Hidalgo, Borja Belandia et al. · 2018 · PLoS ONE
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance
Qingxia Ma, Qianqian Xu, Jiaojiao Zhao, Wen‐Wei Zhang, Qiang Wang, Jing‐Yuan Fang, Zhimin Lu, Jia Liu, Leina Ma · 2021 · Cancer Letters
Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases
Mei-Juan Huang, R. Sun, Qiang Huang, Z. Tian · 2017 · Frontiers in Pharmacology
Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma
Tomomi Hashiba, Taro Yamashita, Hikari Okada, Kouki Nio, Takehiro Hayashi, Yoshiro Asahina, Tomoyuki Hayashi, Takeshi Terashima, Noriho Iida, Hajime Takatori et al. · 2020 · Cellular and Molecular Gastroenterology and Hepatology
Biological evaluation of benzosuberones
Haider Behbehani, Kamal Mohamed Dawood, Thoraya A. Farghaly · 2017 · Expert Opinion on Therapeutic Patents
High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer
Ievgen V. Pylypchuk, Huizhen Suo, Chanakarn Chucheepchuenkamol, Nils Jedicke, Pär A. Lindén, Mikael E. Lindström, Michael Peter Manns, Olena Sevastyanova, Tetyana Yevsa · 2022 · Frontiers in Bioengineering and Biotechnology
Mitochondrial‐Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma
Yizhou Wang, Feihong Song, Xiaofeng Zhang, Cheng Zhi Yang · 2022 · Oxidative Medicine and Cellular Longevity
Direct type I interferon signaling in hepatocytes controls malaria
Camila Marques-da-Silva, Kristen B. Peissig, Michael P. Walker, Justine C. Shiau, Carson Bowers, Dennis E. Kyle, Rahul Vijay, Scott E. Lindner, Samarchith P. Kurup · 2022 · Cell Reports
Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/Twist1 pathway
Jie Yin, Lan Wang, Ji‐Min Zhu, Qian Yu, Ruyi Xue, Ying Fang, Yian Zhang, Yanjie Chen, Taotao Liu, Ling Dong et al. · 2016 · Oncotarget
Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer
Yuling Mao, Liuqing Zhu, Zhijian Huang, Chuanghua Luo, Ti Zhou, Lei Li, Guannan Wang, Zhonghan Yang, Weiwei Qi, Xia Yang et al. · 2019 · Endocrine Related Cancer
Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma
Rossella Farra · 2015 · World Journal of Gastroenterology
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
E Lau, John R. Šedý, Cindy Sander, Misa A. Shaw, Yongmei Feng, Marzia Scortegagna, Giuseppina Claps, Steven E. Robinson, Phil Fang Cheng, Rohith Srivas et al. · 2015 · Oncogene
A phosphokinome‐based screen uncovers new drug synergies for cancer driven by liver‐specific gain of nononcogenic receptor tyrosine kinases
Yannan Fan, María Arechederra, Sylvie Richelme, Fabrice Daian, Chiara Novello, Julien Caldéraro, Luca Di Tommaso, Guillaume Morcrette, Sandra Rebouissou, Matteo Donadon et al. · 2017 · Hepatology
Guaiane‐type Sesquiterpenoid Dimers from Artemisia zhongdianensis and Antihepatoma Carcinoma Activity via the p38MAPK Pathway
Wei Dong, Wenjing Ma, Yun‐Bao Ma, Feng‐Jiao Li, Tian-Ze Li, Yong‐Cui Wang, Xiaofeng He, Chang‐An Geng, Xue‐Mei Zhang, Ji‐Jun Chen · 2023 · Chinese Journal of Chemistry
Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells
Zuzana Saidak, Anne‐Sophie Giacobbi, Christophe Louandre, Chloé Sauzay, Youcef Mammeri, Antoine Galmiche · 2017 · Cancer Letters
CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway
Jiang Chen, Jiang Shi, Huijiang Shao, Bixia Li, Tong Ji, Daniel Staiculescu, Jiayan He, Jie Zhao, Liuxin Cai, Xiao Huan Liang et al. · 2022 · Science China Life Sciences
Proline isomerisation as a novel regulatory mechanism for p38MAPK activation and functions
Anna I. Brichkina, Ngan Nguyen, Rajamanickam Baskar, Sheena Wee, Jayantha Gunaratne, Robert Charles Robinson, Dmitry V. Bulavin · 2016 · Cell Death and Differentiation
PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy
Jian-feng Zheng, Shaozhong He, Zongyue Zeng, Xinqi Gu, Lei Cai, Guangying Qi · 2019 · Molecular Therapy
Genome-Wide DNA Methylation Alterations and Potential Risk Induced by Subacute and Subchronic Exposure to Food-Grade Nanosilica in Mice
Xiaoyan Lu, Junying Li, He Lou, Zeya Cao, Xiaohui Fan · 2021 · ACS Nano
Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers
Inga Hochnadel, Lisa Hoenicke, Nataliia Petriv, Lavinia Neubert, Elena Reinhard, Tatjana Hirsch, Juan Carlos López Alfonso, Huizhen Suo, Thomas Longerich, Robert Geffers et al. · 2022 · Oncogene
Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9
Julia E. Kieckhaefer, Flavio Maina, Rebecca G. Wells, Kirk J. Wangensteen · 2019 · Seminars in Liver Disease
Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
Yongting Lai, Bing Feng, Mubalake Abudoureyimu, Yingru Zhi, Hao Zhou, Ting Wang, Xiaoyuan Chu, Ping Chen, Rui Wang · 2019 · Frontiers in Oncology
Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms
Mandeep Dahiya, Harish Dureja · 2021 · Journal of Chemotherapy
Multidrug Resistance in Hepatocellular Carcinoma
Baojun Duan, Chen Huang, Jun Bai, Yu Lian Zhang, Xi Wang, Juan Yang, Jun Li · 2019 · Codon Publications eBooks
Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Wubin He, Xiaoxu Huang, Bradford K. Berges, Yue Wang, Ni An, Rongjian Su, Yanyan Lu · 2021 · Frontiers in Pharmacology
An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer
Matthew Ashenden, Antoinette van Weverwijk, Nirupa Murugaesu, Antony Fearns, James Campbell, Qiong Gao, Marjan Iravani, Clare M. Isacke · 2017 · Molecular Cancer Therapeutics
Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology
Jia Xin Yu, Amanda J. Craig, Mary E. Duffy, Carlos Villacorta-Martín, Verónica Miguela, Marina Ruiz de Galarreta, Alexander P. Scopton, Lisa Silber, Andres Y. Maldonado, Alexander Rialdi et al. · 2019 · Molecular Cancer Therapeutics
Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14
Matias Antonio Avila, Carmen Berasain · 2015 · Hepatology
The expression and function of miR-622 in a variety of tumors
Juan Lü, Zhongyang Xie, Zhaoying Xiao, Danhua Zhu · 2021 · Biomedicine & Pharmacotherapy
Iridium photosensitizer constructed liposomes with hypoxia-activated prodrug to destrust hepatocellular carcinoma
Shuangling Luo, Chao Liang, Qianling Zhang, Pingyu Zhang · 2022 · Chinese Chemical Letters
Advances in functional genetic screening with transposons and CRISPR/Cas9 to illuminate cancer biology
Kathryn A. O’Donnell · 2018 · Current Opinion in Genetics and Development
SRSF3 and HNRNPH1 Regulate Radiation-Induced Alternative Splicing of Protein Arginine Methyltransferase 5 in Hepatocellular Carcinoma
Chaowei Wen, Zhujun Tian, Lan Li, Tongke Chen, Huajian Chen, Jichen Dai, Zhenzhen Liang, Shumei Ma, Xiaodong Liu · 2022 · International Journal of Molecular Sciences
NEAT1–SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines
Hiroyuki Tsuchiya, Ririko Shinonaga, Hiromi Sakaguchi, Yutaka Kitagawa, Kenji Yoshida · 2023 · Current Issues in Molecular Biology
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment
Stephanie Busche, Katharina John, Franziska Wandrer, Florian W. R. Vondran, Ulrich Lehmann, Heiner H. Wedemeyer, Frank Eßmann, Klaus Schulze‐Osthoff, Heike Bantel · 2021 · Cell Death and Disease
Positive feedback between ROS and cis-axis of PIASxα/p38α-SUMOylation/MK2 facilitates gastric cancer metastasis
Qian Wang, Ci Xu, Qiang Fan, Haihua Yuan, Xin Zhang, Biying Chen, Renjie Cai, Yanjie Zhang, Moubin Lin, Ming Xu · 2021 · Cell Death and Disease
The Role of Bcl‐2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma
Alex José de Melo Silva, Juliana Ellen de Melo Gama, Sheilla Andrade de Oliveira · 2024 · International Journal of Cell Biology
In vivo RNAi screens: concepts and applications
Shane Crotty, Matthew E. Pipkin · 2015 · Trends in Immunology
Alpha fetoprotein antagonises benzyl isothiocyanate inhibition of the malignant behaviors of hepatocellular carcinoma cells
Mingyue Zhu, Wei Li, Junli Guo, Yan Lu, Dong Xu, Bo Lin, Yi Chen, Xueer Zhang, Mengsen Li · 2016 · Oncotarget
Epigenetic silencing of GCH1promotes hepatocellular carcinoma growth by activating superoxide anion-mediated ASK1/p38 signaling via inhibiting tetrahydrobiopterin de novo biosynthesis
Guo‐Chao Zhong, Zhibo Zhao, Yao Cheng, Yunbing Wang, Chan Qiu, Lin‐Hong Mao, Jie‐Jun Hu, Dong Cai, Yan Liu, Jianping Gong et al. · 2021 · Free Radical Biology and Medicine
Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis
Lim, Bryce, Kamal, Aryan, Gomez Ramos, Borja, Adrian Segarra, Juan M., Ibarra, Ignacio L., Dignas, Lennart, Kindinger, Tim, Volz, Kai, Rahbari, Mohammad, Rahbari, Nuh et al. · 2025 · Nature Genetics
Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma
Taian Lin, Yixuan Hou, Xueqing Liu, Ihsan Ullah, Siyu Qiu, Zi-Dong Lu, Jianyong Qi, Youyong Yuan · 2025 · ACS Nano
The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound
Wanting Hou, Hongwei Xia, Sheng Zhou, Zhenhai Fan, Huanji Xu, Qiyong Gong, Yongzhan Nie, Qiulin Tang, Feng Bi · 2019 · Translational Cancer Research
Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer
Sarah Yoon, Eun‐Ju Lee, Ji Hye Choi, Taek Chung, Do Young Kim, Jong-Yeop Im, Myung-Ho Bae, Jung‐Hee Kwon, Hyuk-Hoon Kim, Hyung Chul Kım et al. · 2018 · Oncogene
High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo
Yinzong Xiao, Lun‐Quan Sun, Yongming Fu, Yan Huang, Rongrong Zhou, Xingwang Hu, Pengcheng Zhou, Jun Quan, Ning Li, Xuegong Fan · 2017 · BMC Cancer
Mouse models in the era of large human tumour sequencing studies
Julian R. de Ruiter, Lodewyk F.A. Wessels, Jos Jonkers · 2018 · Open Biology
CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia
Jesús Duque‐Afonso, Chiou-Hong Lin, Kyuho Han, David W. Morgens, Edwin E. Jeng, Ziming Weng, Johan Jeong, Stephen H.K. Wong, Li Zhu, Michael C. Wei et al. · 2018 · Cancer Research
Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinoma
Qing‐Quan Liu, Yu‐Wen Liu, Yuan‐Kang Xie, Jianhong Zhang, Cai‐Xin Song, Jian‐Zhong Wang, Binhui Xie · 2021 · Cell Biology International
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer
Ramona Rudalska, Jule Harbig, Michael Förster, Pascal Woelffing, Aylin Esposito, Mark Kudolo, Adelina Botezatu, Vanessa Haller, Nicole Janssen, Samuel J. Holzmayer et al. · 2025 · Nature Cancer
p38MAPK family isoform p38α and activating transcription factor 2 are associated with the malignant phenotypes and poor prognosis of patients with ovarian adenocarcinoma
Wan-Juan Song, Yu Dong, Cheng Luo, Yuanyuan Chen · 2017 · Pathology - Research and Practice
Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
Yuxiang Wang, Xu Zhang, Qingyang Ma, Landian Hu, Xi Zhang, Yi Wang, Lan Xu, Chunhao Yang, Cun Tan, Xiangyin Kong et al. · 2021 · Cell Death and Disease
Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors
Niklas M. Tormählen, Mariella Martorelli, Annette Kühn, Florian Maier, Jamil Guezguez, Michael W. M. Burnet, Wolfgang Albrecht, Stefan Laufer, Pierre Koch · 2021 · Journal of Medicinal Chemistry
Functional Genomics for Cancer Research: Applications In Vivo and In Vitro
Thomas A. O’Loughlin, Luke A. Gilbert · 2018 · Annual Review of Cancer Biology
Based on Integrated Bioinformatics Analysis Identification of Biomarkers in Hepatocellular Carcinoma Patients from Different Regions
Linxin Teng, Kaiyuan Wang, Yu Liu, Yanxia Ma, Weiping Chen, Lei Bi · 2019 · BioMed Research International
Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships
Marco Breinig, Artem Lomakin, Elyas Heidari, Michael A. Ritter, Gleb D. Rukhovich, Lio Böse, Luise Butthof, Lena Wendler-Link, Hendrik Wiethoff, Tanja Poth et al. · 2025 · Nature Biomedical Engineering
Mfap4: a promising target for enhanced liver regeneration and chronic liver disease treatment
Viktoriia Iakovleva, Anna Wuestefeld, Agnes Bee Leng Ong, Rong Gao, Neslihan Arife Kaya, May Yin Lee, Weiwei Zhai, Wai Leong Tam, Yock Young Dan, Torsten Wüestefeld · 2023 · npj Regenerative Medicine
CRISPR Libraries and Screening
John Thomas Poirier · 2017 · Progress in molecular biology and translational science
Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma
Shusil K. Pandit, Giada Sandrini, Jessica Merulla, Valentina Nobili, Xin Wang, Alessia Zangari, Andrea Rinaldi, Dheeraj A. Shinde, Giuseppina Maria Carbone, Carlo Vittorio Catapano · 2021 · Cancers
Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway
Wenbo Ding, Xiuwei Chen, Licheng Yang, Yaping Chen, Jie Song, Weiquan Bu, Bin Feng, Meng Zhang, Yi Luo, Xiao‐Bin Jia et al. · 2022 · Integrative Cancer Therapies
Biological features and biomarkers in hepatocellular carcinoma
Tetsuhiro Chiba · 2015 · World Journal of Hepatology
Cellular Origin of Hepatocellular Carcinoma
Doris Schneller, Peter E. Angel · 2019 · Codon Publications eBooks
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma
Yu Jin Cho, Wonyoung Kang, Sung Heon Kim, Jason K. Sa, NAYOUNG KIM, Patrick J. Paddison, Misuk Kim, Kyeung Min Joo, Young‐il Hwang, Do‐Hyun Nam · 2016 · International Journal of Oncology
Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma
Jie Qin, Qianyi Gong, Cheng Shuang Zhou, Jietian Xu, Yifei Cheng, Weiyue Xu, Di Zhu, Yiming Liu, Yuye Zhang, Yanru Wang et al. · 2025 · Signal Transduction and Targeted Therapy
Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
Maria Chiara Anania, Tiziana Di Marco, Mara Mazzoni, Angela Greco · 2020 · Cancers
MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
Zhong Wan, Tingyu Liu, Liang Wang, Rong Wang, Hai Zhang · 2020 · Aging
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem
Benjamin J. McLean, Aji Istadi, Teleri Clack, Mezzalina Vankan, Daniel Schramek, G. Gregory Neely, Marina Pajic · 2022 · Advanced Genetics
PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma
Yu Sha, Mingang Pan, Yunmeng Chen, Liangjun Qiao, Hengyu Zhou, Dina Liu, Wenlu Zhang, Kai Wang, Luyi Huang, Ni Tang et al. · 2023 · Cell Death Discovery
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond
Martina Minisini, Martina Mascaro, Claudio Brancolini · 2024 · Cancer Drug Resistance
Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro
Huizhen Suo, Inga Hochnadel, Nataliia Petriv, Raimo Franke, Jennifer Schmidt, Н. В. Ліманська, Alisa Tugai, Nils Jedicke, Mark Bröenstrup, Michael Peter Manns et al. · 2022 · Frontiers in Pharmacology
The BH3‐only protein BID impairs the p38‐mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice
Johanna Orlik, Sven Schüngel, Laura Elisa Buitrago‐Molina, Silke Marhenke, Robert Geffers, Jessica Endig, Katharina Lobschat, Stephanie K. Roessler, Benjamin Frank Goeppert, Michael Peter Manns et al. · 2015 · Hepatology
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma
Ming Li, Wei Wang, Yuzhen Dan, Zhangwei Tong, Wenbo Chen, Liping Qin, Kun Liu, Wengang Li, Pingli Mo, Chundong Yu · 2016 · Oncotarget
Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis
Philipp Guenthoer, Kerstin Fuchs, Gerald Reischl, Leticia Quintanilla‐Martínez, Irene González-Menéndez, Stefan Laufer, Bernd Jürgen Pichler, Manfred Kneilling · 2019 · Inflammopharmacology
Reports from the International Liver Cancer Association (ILCA) congress 2014
Jean‐Charles Nault · 2014 · Journal of Hepatology
An integrative pan-cancer analysis of MASP1 and the potential clinical implications for the tumor immune microenvironment
Hongjun Yu, Chaoqun Wang, Shanjia Ke, Yanan Xu, Shounan Lu, Zhigang Feng, Miaoyu Bai, Baolin Qian, Yue Xu, Zihao Li et al. · 2024 · International Journal of Biological Macromolecules
Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication
Heike Bantel, Ali E. Canbay · 2018 · Gut
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor
Jing Hu, Jing Zhang, Feifei Sun, Mei Qi, Peng Su, Hui Liu, Lin Gao, Meng Jiao, Zhen Wu, Lei Xiang et al. · 2019 · Anti-Cancer Drugs
Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11
Anne Gaza, VALERIE K. FRITZ, Lara Malek, Laura Wormser, Nora Treiber, Johannes Danner, Andreas Emanuel Kremer, Wolfgang Erwin Thasler, Jürgen Siebler, Gunter Meister et al. · 2021 · Neoplasia
The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Michalis Mastri, Spencer R. Rosario, Amanda Tracz, Robin E. Frink, Rolf A. Brekken, John M.L. Ebos · 2016 · Current Drug Targets
Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
Susana Llerena, Nuria García‐Díaz, Soraya Curiel‐Olmo, Antonio Agraz-Doblás, Agustín García-Blanco, Helena Pisonero, Marı́a Varela, Miguel Santibáñez, Carmen Almaráz, Laura Cereceda et al. · 2018 · Oncotarget
RABL2A–CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma
Mingxiu Zhou, Xue Chen, Hansong Bai, Yuemei Sun, Zican Zhang, Simin Li, Xiaoshan Wang, Ming Zeng · 2021 · DNA and Cell Biology
DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC)
Fernando Carazo, Cristina Bértolo, Carlos Castilla, Xabier Cendoya, Lucía Campuzano, Diego Serrano, Marian Gimeno, Francisco J. Planes, Rubén Pı́o, Luis M. Montuenga et al. · 2020 · Cancers
Use of DNA transposons for functional genetic screens in mouse models of cancer
Camino Bermejo‐Rodríguez, Pedro Antonio Pérez-Mancera · 2015 · Current Opinion in Biotechnology
Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma
VALERIE K. FRITZ, Lara Malek, Anne Gaza, Laura Wormser, Majken Appel, Andreas Emanuel Kremer, Wolfgang Erwin Thasler, Jürgen Siebler, Markus Friedrich Neurath, Claus Hellerbrand et al. · 2021 · Cancers
From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis
Aikaterini F. Giannopoulou, Athanassios D. Velentzas, Athanasios K. Anagnostopoulos, Adamantia Agalou, Nikolaos C. Papandreou, Stamatia A. Katarachia, Dimitra G. Koumoundourou, Eumorphia G. Konstantakou, Vasiliki I. Pantazopoulou, Anastasios D. Delis et al. · 2021 · Cancers
G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma
SHAO-KUAN CHEN, Yen‐Chieh Wang, TAI-YUAN LIN, Hsin-Jou Wu, Chi‐Jung Huang, Wei‐Chi Ku · 2021 · Cancer Genomics & Proteomics
Dynamic Interplay between the Transcriptome and Methylome in Response to Oxidative and Alkylating Stress
Lize Deferme, Jarno E.J. Wolters, Sandra M.H. Claessen, Daniel H. J. Theunissen, Twan van den Beucken, J. Richard Wagner, Simone G. J. Van Breda, Jos C. S. Kleinjans, Jacob J. Briedé · 2016 · Chemical Research in Toxicology